Latest Publications
Additional Research on Bedaquiline Salts recently published in Acta Crystallographica
Improved Pharma is pleased to announce an additional open-source publication describing the structures of Bedaquiline maleate salts that is now available to download. Previously, our lab was able to identify promising new benzoate salts of Read more
Improved Pharma has Expanded their Laboratory Space to Support the Growing Business
WEST LAFAYETTE, IND. (PRWEB) APRIL 26, 2021 Improved Pharma is delighted to announce the expansion of its current laboratory to accommodate additional research capabilities. The addition of the newly acquired laboratory facility in the Purdue Read more
Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics
Dr, Stephen Byrn, CSO of Improved Pharma, was a key contributor to a recent publication describing the usefulness of mini-tablets in monitoring the dose-response of lapatinib solid amorphous dispersions in juvenile pigs. Juvenile pigs have been well-established Read more
Improved Pharma announces new publication on amorphous dispersions
A recent collaboration with our colleagues further advances the field of X-ray pair distribution function analysis applied to the analysis of amorphous solid dispersions. In this paper, we present the results of different polymer:flubendazole Read more
Control of Nitrosamine Impurities in Human Drugs
In February 2021, the FDA issued a guidance aimed at preventing unacceptable levels of nitrosamine impurities in pharmaceutical products. This guidance required a risk assessment to be completed by March 31, 2021. This is because Read more
Recent research on bedaquiline selected for the November cover of Acta Crystallographic
Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US as the Read more